VOR
Vor Biopharma Inc

1,857
Loading...
Loading...
News
all
press releases
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
A late-stage clinical study in China conducted by Vor Bio’s collaborator RemeGen Co., which is evaluating Telitacicept in adults with primary Sjögren's disease, achieved the primary endpoint of improving disease activity compared to placebo.
Stocktwits·25d ago
News Placeholder
More News
News Placeholder
Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why
The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.
Zacks·2mo ago
News Placeholder
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
Vor Biopharma Secures $55.6M for Cancer Therapy Trials...
Yahoo! Finance: News·8mo ago
News Placeholder
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that...
Business Wire·1y ago
News Placeholder
Vor Biopharma (VOR) Receives a Buy from Barclays
Barclays analyst Carter Gould maintained a Buy rating on Vor Biopharma (VOR Research Report) today and set a price target of $3.00. The company's...
TipRanks Financial Blog·1y ago
News Placeholder
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Globe Newswire·1y ago
News Placeholder
Vor Biopharma GAAP EPS of -$0.39 beats by $0.11
Vor Biopharma GAAP EPS of -$0.39 beats by $0.11...
SeekingAlpha.com: All News·1y ago
News Placeholder
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Globe Newswire·1y ago
News Placeholder
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of March 1, 2024, the...
Globe Newswire·2y ago
News Placeholder
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Globe Newswire·2y ago

Latest VOR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.